REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
12

Sermorelin Journey — Month 3 Check-In

Zion Foley·about 2 months ago
Month 3 check-in for my Sermorelin journey. Quick recap: 35-year-old, recreational athlete, running this primarily for recovery and longevity goals. Month 1 was the adjustment period. Getting used to the routine, dialing in timing and injection technique. Minimal noticeable effects beyond placebo territory. Month 2 is when things got interesting. Sleep metrics improved across the board. HRV started trending upward. Recovery between training sessions shortened. I was hitting PR territory in the gym which I attribute partly to being able to train harder and more frequently. Month 3 has been about maintaining the gains. The dramatic improvement phase seems to be over, replaced by a steady state of enhanced baseline function. I feel notably better than pre-protocol but the week-to-week improvements have leveled off. Interesting observation: I took a long weekend trip in month 2 and missed 3 consecutive doses. Did not notice any immediate decline, which suggests the effects are more cumulative than acute. Resumed dosing when I returned and everything stayed on track. Planning to continue for one more month and then take a 6-week break to see how much of the benefit persists.

Comments (4)

Casey BaldwinDEMO·about 2 months ago

Question for you: did you get bloodwork done before and during your Sermorelin protocol? I am about to start and trying to decide which panels to run. Obviously the basics but curious if there are any specific markers that are particularly informative for tracking Sermorelin response.

3
Logan DanielsDEMO·about 2 months ago

I ran Sermorelin at a slightly higher dose than what you used and found the results were actually about the same. This lines up with the dose-response data suggesting there is a ceiling effect. Higher dose just meant more injection site irritation without additional benefit. Your approach seems well-calibrated.

4
Jules ChristensenDEMO·about 2 months ago

The sleep improvement you mention with Sermorelin has been the most universally reported benefit I see across different users. It seems like regardless of primary goals, almost everyone reports better sleep quality. I wonder if this is a direct effect or downstream from other physiological changes.

5
Zev DuncanDEMO·about 2 months ago

Thanks for the detailed protocol breakdown. I am starting Sermorelin next week and this is exactly the kind of practical information I was looking for. The reconstitution tips especially — I have seen conflicting advice elsewhere about water temperature and injection speed. Your approach sounds well-reasoned.

2

Sign in to comment.